During the Spring Festival, China has been facing a difficult time as the coronavirus spread all over the country. In order to stop the coronavirus, we look forward to the effective prevention and control to stop the outbreak of the virus and the symptomatic treatment. We also hope the anti-virus vaccines and drugs could be developed and put into use as soon as possible. Medicilon involuntarily steps forward at this critical moment. As a new drug R&D enterprise and to show the social responsibility, we have funds, technology and equipment to fight the outbreak of the coronavirus with professionalism.
Technology Assistance: Medicilon provides drug safety evaluation research for coronavirus vaccine R&D at no cost, with an estimated R&D cost of RMB 4 million
On January 31, Medicilon, the team of Dr. Chen Ling of the State Key Laboratory of Respiratory Diseases (SKLRD) and Guangzhou nBioMed have reached a scientific research collaboration agreement. The three parties will establish a strategic collaborative partnership to integrate the advantages and strength of all parties to develop the new coronavirus vaccine.
SKLRD is the only state key laboratory in the field of respiratory disease research in China, relying on the Guangzhou Medical University and was approved by the Ministry of Science and Technology in October 2007. The first director of the laboratory was Academician Dr. Zhong Nanshan, who is the Chinese epidemiologist and pulmonologist who discovered the SARS coronavirus in 2003.
Medicilon plans to invest RMB 4 million in research collaboration with the above-mentioned laboratories. In addition, Medicilon will also provide preclinical drug safety evaluation for the development of new coronavirus vaccines for free. With its own innovative research and development technology platform, the fastest Degree to assist the vaccine development process, so that the vaccine can be put into use as soon as possible. With our own innovative research and development technology platform, this will help the vaccine development process at the fastest speed, so that the vaccine can be put into use as soon as possible. The three parties collaboration was docked by Professor Peng Shuangqing, VP of Preclinical, who was the key person in charge of the safety evaluation of the Ebola virus vaccine. In the efforts to combat the epidemic and to actively collaborate with the laboratories, Medicilon will continue to adhere to the “Focus on Innovation and Dedicated Service”.
Funding Support: Medicilon donates RMB 1 million to Shanghai Red Cross Foundation to fight the epidemic
While developing the vaccine, we will not forget the frontline staff who is fighting the coronavirus and infected patients. On February 1, Medicilon donated RMB 1 million to the Shanghai Red Cross Foundation’s special donation project for “New Coronavirus Infected Pneumonia Epidemic Prevention and Control Project” in order to ease the problem of material shortage in Wuhan, Hubei. The donation gives our hearts and respects to the doctors and nurses!